Antiviral treatment or mAbs for persistent SARS-COV-2 infection in patients with hematologic malignancies: A case series
J Med Virol
.
2023 Jun;95(6):e28865.
doi: 10.1002/jmv.28865.
Authors
Ignacio Pérez-Catalán
1
,
Iris Gómez-Alfaro
2
,
Sergio García-Muñoz
3
,
Celia Roig-Martí
1
,
Noelia Rodríguez-Lozano
2
,
Sergio Fabra-Juana
1
,
María-José Esteve-Gimeno
1
,
Adriana Gascón-Buj
4
,
Carmen Freiria-Alberte
4
,
Juana Clavel-Pia
4
,
Miguel Torres-García
5
,
Roberto Reig-Valero
6
,
Raúl Ferrando-Piqueres
3
,
Lidón Mateu-Campos
6
,
Jorge Usó-Blasco
1
,
José-Manuel Ramos-Rincón
7
Affiliations
1
Internal Medicine, General University Hospital of Castellón, Castellón de la Plana, Spain.
2
Clinical Microbiology, General University Hospital of Castellón, Castellón de la Plana, Spain.
3
Pharmacy, General University Hospital of Castellón, Castellón de la Plana, Spain.
4
Hematology, General University Hospital of Castellón, Castellón de la Plana, Spain.
5
Pneumology, General University Hospital of Castellón, Castellón de la Plana, Spain.
6
Intensive Care Medicine, General University Hospital of Castellón, Castellón de la Plana, Spain.
7
Internal Medicine, General University Hospital of Alicante, Alicante, Spain.
PMID:
37314151
DOI:
10.1002/jmv.28865
No abstract available
Publication types
Letter
MeSH terms
COVID-19*
Hematologic Neoplasms* / complications
Humans
Research
SARS-CoV-2